Detalles de la búsqueda
1.
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors.
Tumori
; 108(1): 47-55, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34002648
2.
Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers.
Front Oncol
; 11: 700853, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34552867
3.
Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature.
Cancers (Basel)
; 13(21)2021 Oct 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-34771566
4.
Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: a case report.
Transl Lung Cancer Res
; 9(3): 787-792, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32676339
5.
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors.
Ther Adv Med Oncol
; 12: 1758835920952994, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33193825
6.
Optimizing PD-L1 evaluation on cytological samples from advanced non-small-cell lung cancer.
Immunotherapy
; 12(3): 183-193, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32066299
7.
High levels of Notch intracellular cleaved domain are associated with stemness and reduced bevacizumab efficacy in patients with advanced colon cancer.
Oncol Rep
; 42(6): 2750-2758, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31578584
8.
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC.
Ther Adv Med Oncol
; 11: 1758835919885540, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31798692
9.
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC.
Lung Cancer
; 131: 78-85, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31027702
10.
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC.
J Exp Clin Cancer Res
; 38(1): 222, 2019 May 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-31138260
11.
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab.
Immunotherapy
; 10(8): 681-694, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29882691
12.
Fingerprint Change: Not Visible, But Tangible.
J Forensic Sci
; 62(5): 1372-1373, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28605025
13.
ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients.
Diagn Cytopathol
; 43(11): 941-6, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26152804
14.
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method.
PLoS One
; 10(11): e0142891, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26571236
15.
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.
J Thorac Oncol
; 13(6): e89-e91, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29596911
16.
L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.
J Thorac Oncol
; 11(10): e121-3, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27257132
Resultados
1 -
16
de 16
1
Próxima >
>>